Want to see URGN full AI Analyst Report?
URGN Stock Chart & Stats
$46.36
$0.54(1.32%)
At close: 4:00 PM EDT
$46.36
$0.54(1.32%)
Day’s Range― - ―
52-Week Range$15.86 - $50.81
Previous CloseN/A
Volume333.78K
Average Volume (3M)764.86K
Market Cap
$1.98B
Enterprise Value$1.94K
Total Cash (Recent Filing)$107.97M
Total Debt (Recent Filing)$196.13M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 05, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding48,880,566
10 Day Avg. Volume799,832
30 Day Avg. Volume764,858
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)-10.68
Price to Sales (P/S)10.26
P/FCF Ratio-6.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$60.20Price Target Upside29.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$322.20M
Bulls Say, Bears Say
Bulls Say
ZUSDURI Commercial TractionRapid ZUSDURI revenue growth and expanding repeat utilization indicate meaningful early product-market adoption across healthcare settings. If this conversion continues, the launch can diversify revenue beyond JELMYTO and create a larger commercial base to support future operating leverage.
Strong Product EconomicsHigh and consistent gross margins suggest the commercial products have attractive underlying economics before operating expenses. Combined with strong revenue growth, this provides a foundation for eventual operating leverage if commercialization investments moderate as the franchise scales.
Long-term Franchise ProtectionPotential patent protection into 2044 can extend the commercial life of key products and support durable returns on development investment. Advancing UGN-103, UGN-104 and UGN-501 also creates opportunities to broaden the oncology portfolio beyond current products.
Bears Say
Persistent Operating LossesDeep and persistent operating losses show that strong gross margins have not yet translated into a sustainable earnings model. Continued losses can constrain strategic flexibility and leave profitability dependent on substantial revenue growth, disciplined spending, or both.
Cash Burn And Balance-sheet PressureMaterial cash consumption combined with negative equity and higher debt increases the company’s funding dependence before profitability is achieved. This weakens financial flexibility and could make future investment, refinancing, or balance-sheet repair more difficult.
Commercial Execution RiskThe gap between activated sites and prescribers indicates that access does not yet guarantee utilization, leaving the launch dependent on continued physician conversion and repeat prescribing. Limited guidance also makes the pace of revenue scaling and investment payback less certain.
Urogen Pharma News
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $15.86 and its highest was $50.81 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $1.98B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 35 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Aug 05, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.265 by -$0.015.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is 0.1.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 48,880,566 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.265. Following the earnings report the stock price went up 16.308%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in URGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.20 (29.85% Upside)
$60.20 (29.85% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 86%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 59.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
URGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong positive momentum driven by the ZUSDURI launch (Q2 ZUSDURI revenue of $50.4M, rapid growth in activated accounts and prescribers, durable Phase III durability data, pipeline progress, favorable IP outcomes and materially higher total revenue). Management acknowledged measured near-term risks including continued operating expense increases, quarter-to-quarter variability, remaining net loss (though substantially improved), and early-stage adoption dynamics. They reinforced confidence in cash sufficiency to reach profitability while accelerating investments to support long-term growth.View all URGN earnings summariesURGN Stock 12 Month Forecast
Average Price Target
$60.20
▲(29.85% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
1.77% Insiders
5.16% Mutual Funds
43.99% Other Institutional Investors
41.55% Public Companies and
Individual Investors